综述

临床诊断与治疗的新工具——可变淋巴细胞受体

展开
  • 1. 辽宁师范大学生命科学学院, 大连116081 2. 辽宁师范大学海洋生物功能基因及蛋白质组学研究所, 大连 116081

收稿日期: 2012-08-07

  修回日期: 2012-11-09

  网络出版日期: 2013-01-25

基金资助

国家自然科学基金项目(编号:31071991)和辽宁省教育厅科研项目(编号:LT2010056)资助

Variable lymphocyte receptors: the novel tool for clinical diagnosis and therapy

Expand
  • 1. College of Life Sciences, Liaoning Normal University, Dalian 116081, China 2. Institute of Marine Genomics & Proteomics, Liaoning Normal University, Dalian 116081, China

Received date: 2012-08-07

  Revised date: 2012-11-09

  Online published: 2013-01-25

摘要

单克隆抗体(Monoclonal antibody, mAb)在癌症以及自身免疫等疾病的诊断与治疗中得到广泛应用, 并且取得了重大进展。当今应用于临床的单克隆抗体是在免疫球蛋白的基础上进行改造研发而得。然而近期发现的无颌类脊椎动物的特异性抗原受体—可变淋巴细胞受体(Variable lymphocyte receptor, VLR), 为抗体类试剂或药物的研发提供了新的视角。与免疫球蛋白(Immunoglobulins, Ig)相比, VLR与抗原结合的特异性、亲和力及稳定性都优于Ig类抗体, 并且抗原特异性单克隆VLR的制备技术日趋成熟。因此, VLR在临床诊断和治疗中具有更高的应用价值, 并可能成为新一代的抗体药物。文章就VLR的基本特征、制备方法及其应用前景进行综述, 为实现VLR在临床诊断与治疗等领域中的应用提供有益参考。

本文引用格式

于涛,韩英伦,肖蓉,刘欣,李庆伟 . 临床诊断与治疗的新工具——可变淋巴细胞受体[J]. 遗传, 2013 , 35(1) : 55 -61 . DOI: 10.3724/SP.J.1005.2013.00055

Abstract

Monoclonal antibodies, which are widely applied to the diagnosis and therapy of cancers as well as autoimmune diseases, have been made significant progresses. Currently, the monoclonal antibodies for clinical applications are mostly based on the modified immunoglobulins. However, the variable lymphocyte receptors (VLRs), which are recently discovered as specific antigen receptors of jawless vertebrates, provide a new perspective for the development of antibody reagents and drugs. Compared with immunoglobulins, the antigen-binding specificity, affinity and stability of VLRs-based antibodies are better. In addition, the production technology of antigen-specific monoclonal VLRs has become more and more mature. Therefore, the VLRs have a higher clinical value and may become the next-generation antibody drug. This review focuses on the basic feature, production method and application prospect of VLRs, which provides valuable clues for the applications of VLRs in the field of clinical diagnosis and therapy.

参考文献

[1] Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer, 2012, 12(4): 278-287.
[2] Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell, 2012, 148(6): 1081-1084.
[3] Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther, 2012, 91(4): 635 -646.
[4] Chugh PK. Lupus: novel therapies in clinical development. Eur J Intern Med, 2012, 23 (3): 212-218.
[5] Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on dis-covery research and clinical validation. Curr Pharm Biotechno, 2008, 9(6): 502-509.
[6] Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotech, 2007, 18(4): 295-304.
[7] Pancer Z, Amemiya CT, Ehrhardt GRA, Ceitlin J, Gartland GL, Cooper MD. Somatic diversification of variable lym-phocyte receptors in the agnathan sea lamprey. Nature, 2004, 430(6996): 174- 180.
[8] Alder MN, Herrin BR, Sadlonova A, Stockard CR, Grizzle WE, Gartland LA, Gartland GL, Boydston JA, Turnbough CL Jr, Cooper MD. Antibody responses of variable lym-phocyte receptors in the lamprey. Nat Immunol, 2008, 9(3): 319-327.
[9] Herrin BR, Alder MN, Roux KH, Sina C, Ehrhardt GR, Boydston JA, Turnbough CL Jr, Cooper MD. Structure and specificity of lamprey monoclonal antibodies. Proc Natl Acad Sci USA, 2008, 105 (6): 2040-2045.
[10] Pancer Z, Saha NR, Kasamatsu J, Suzuki T, Amemiya CT, Kasahara M, Cooper MD. Variable lymphocyte receptors in hagfish. Proc Natl Acad Sci USA, 2005, 102(26): 9224-9229.
[11] Kasamatsu J, Sutoh Y, Fugo K, Otsuka N, Iwabuchi K, Kasahara M. Identification of a third variable lymphocyte receptor in the lamprey. Proc Natl Acad Sci USA, 2010, 107(32): 14304- 14308.
[12] Rogozin IB, Iyer LM, Liang L, Glazko GV, Liston VG, Pavlov YI, Aravind L, Pancer Z. Evolution and diversifi-cation of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nat Immunol, 2007, 8(6): 647-656.
[13] Nagawa F, Kishishita N, Shimizu K, Hirose S, Miyoshi M, Nezu J, Nishimura T, Nishizumi H, Takahashi Y, Hashimoto SI, Takeuchi M, Miyajima A, Takemori T, Otsuka AJ, Sakano H. Antigen-receptor genes of the agnathan lamprey are assembled by a process involving copy choice. Nat Immunol, 2007, 8(2): 206-213.
[14] Alder MN, Rogozin IB, Iyer LM, Glazko GV, Cooper MD, Pancer Z. Diversity and function of adaptive immune receptors in a jawless vertebrate. Science, 2005, 310(5756): 1970-1973.
[15] Han BW, Herrin BR, Cooper MD, Wilson IA. Antigen recognition by variable lymphocyte receptors. Science, 2008, 321(5897): 1834-1837.
[16] Boehm T, McCurley N, Sutoh Y, Schorpp M, Kasahara M, Cooper MD. VLR-based adaptive immunity. Annu Rev Immunol, 2012, 30(1): 203-220.
[17] Flajnik MF, Kasahara M. Origin and evolution of the adaptive immune system: genetic events and selective pressures. Nat Rev Genet, 2010, 11(1): 47-59.
[18] Kim HM, Oh SC, Lim KJ, Kasamatsu J, Heo JY, Park BS, Lee H, Yoo OJ, Kasahara M, Lee JO. Structural diversity of the hagfish variable lymphocyte receptors. J Biol Chem, 2007, 282(9): 6726-6732.
[19] Velikovsky CA, Deng L, Tasumi S, Iyer LM, Kerzic MC, Aravind L, Pancer Z, Mariuzza RA. Structure of a lamprey variable lymphocyte receptor in complex with a protein antigen. Nat Struct Mol Biol, 2009, 16(7): 725-730.
[20] Tasumi S, Velikovsky CA, Xu G, Gai SA, Wittrup KD, Flajnik MF, Mariuzza RA, Pancer Z. High- affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci USA, 2009, 106(31): 12891-12896.
[21] Deng L, Velikovsky CA, Xu G, Iyer LM, Tasum
文章导航

/